CL Colgate-Palmolive

8-K Current Report

Filed: March 12, 2026

Health Care

Perfumes, Cosmetics & Other Toilet Preparations

Colgate-Palmolive (CL) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 5.02 · Departure/Election of Directors or Officers

• New board member: Christopher Boerner, Ph.D., 55 — current Board Chair & CEO of Bristol-Myers Squibb, joins CL board effective March 15, 2026
• Boerner brings global pharma/healthcare leadership; previously BMS COO, CCO, and earlier roles at Seattle Genetics, Genentech, McKinsey

+2 more insights

Other Colgate-Palmolive 8-K Filings

8-K Mar 17, 2026

Get deeper insights on Colgate-Palmolive

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.